<p>11 月 19 日（路透社）- Eyepoint Pharmaceuticals Inc (EYPT.O)：
* Eyepoint 宣佈獨立數據安全監測委員會對 Duravyu™ 在濕性年齡相關性黃斑變性中的關鍵第三階段試驗給予積極推薦。
* Eyepoint Pharmaceuticals Inc - Lugano 的頂線數據預計在 2026 年中期發佈。</p>

EYPT

<p>11 月 19 日（路透社）- Eyepoint Pharmaceuticals Inc：* Eyepoint 宣佈獨立數據安全監測委員會對 Duravyu™在濕性年齡相關性黃斑變性中的關鍵第三階段試驗給予積極推薦 * Eyepoint Pharmaceuticals Inc - Lugano 的頂線數據預計在 2026 年中期發佈 來源文本：進一步的公司報道：</p>

<p>Nov 19 (Reuters) - EyePoint Pharmaceuticals Inc (EYPT.O) :
* EYEPOINT ANNOUNCES POSITIVE RECOMMENDATION FROM INDEPENDENT DATA SAFETY MONITORING COMMITTEE FOR PIVOTAL PHASE 3 TRIALS FOR DURAVYU™ IN WET AGE-RELATED MACULAR DEGENERATION
* EYEPOINT PHARMACEUTICALS INC - TOPLINE DATA FOR LUGANO EXPECTED MID-2026 Source text: Further company coverage: (EYPT.O)</p>
<div class="lb-trans"><p>11 月 19 日（路透社）- Eyepoint Pharmaceuticals Inc (EYPT.O)：
* Eyepoint 宣佈獨立數據安全監測委員會對 Duravyu™ 在濕性年齡相關性黃斑變性中的關鍵第三階段試驗給予積極推薦。
* Eyepoint Pharmaceuticals Inc - Lugano 的頂線數據預計在 2026 年中期發佈。</p>
</div>

Eyepoint 宣佈數據安全監測委員會對 Duravyu 的三期試驗給予了積極的推薦